Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (291-300 of 461) with videos related to

Pageof 47
Sort By:
Biological Psychiatry|December 5, 1997
Effect of antipanic treatment on response to carbon dioxideJ M Gorman, S T Browne, L A Papp, et al.
The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.
Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
The Journal of Investigative Dermatology|May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trialKim A Papp, Cathy Reid, Peter Foley, et al.
BMC Dermatology|October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trialKim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
Journal of the American Academy of Dermatology|April 19, 2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)Jeffrey Crowley, Diamant Thaçi, Pascal Joly, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Pageof 47

Showing results (291-300 of 461) with videos related to

Sort By:
Pageof 47
Biological Psychiatry|December 5, 1997
Effect of antipanic treatment on response to carbon dioxideJ M Gorman, S T Browne, L A Papp, et al.
The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.
Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.
Dermatology and Therapy|December 23, 2022
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE RegistryMelinda Gooderham, Kim A Papp, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
The Journal of Investigative Dermatology|May 25, 2012
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trialKim A Papp, Cathy Reid, Peter Foley, et al.
BMC Dermatology|October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trialKim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
Journal of the American Academy of Dermatology|April 19, 2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)Jeffrey Crowley, Diamant Thaçi, Pascal Joly, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
Journal of the American Academy of Dermatology|March 12, 2005
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialCraig L Leonardi, Kim A Papp, Kenneth B Gordon, et al.
Pageof 47